Recent studies suggest a complex interplay between CXCR4 and S1P1 signaling in conditions such as multiple myeloma, glioblastoma, and neurodegenerative diseases, where CXCR4 is a primary therapeutic target [99–101]. The gene discussed is S1PR1; the disease is plasma cell myeloma.